Open AccessSafety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients
Author(s) -
Gregory Mak,
Aimee M Dassner,
Benjamin Hammer,
Benjamin Hanisch
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003263
Subject(s) - tolerability , medicine , monoclonal antibody , covid-19 , monoclonal , antibody , monoclonal antibody therapy , disease , immunology , adverse effect , virology , infectious disease (medical specialty) , outbreak
There is a little data regarding safety or efficacy of monoclonal antibody treatment for mild-to-moderate COVID-19 in pediatric patients despite it being frequently used in adults. This retrospective study of 17 patients with mild-to-moderate COVID-19 who received monoclonal antibody therapy found that the treatment was well tolerated, safe, and may be effective in halting progression to severe disease.